Benefit of Direct-acting Antiviral Therapy in Hepatitis C Virus (HCV) Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- Cryoglobulin level at the end of therapy
研究概览
简要总结
Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.
详细描述
We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin clearance.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hepatitis C virus (HCV) infected patients
- •symptomatic or asymptomatic mixed cryoglobulinemia
- •coinfected or not with HIV
- •treated by direct-acting antiviral (DAA) treatment
- •at least one cryoglobulin measurement before and after DAA
排除标准
- 未提供
研究组 & 干预措施
HCV patients with mixed cryoglobulinemia
HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
干预措施: DAA treatment (Drug)
结局指标
主要结局
Cryoglobulin level at the end of therapy
时间窗: End of treatment (12 or 24 weeks)
The primary outcome was the cryoglobulin level at the end of direct-acting antiviral treatment (week 12 or 24 according to treatment duration)
次要结局
未报告次要终点